CheckMan Stock Market Overview

Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) now carries a market capitalization of a little more than $300 billion as of July 3, 2026, which has taken many investors on a nice ride, given the company's the software-with-a-defense-flavor story.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Commvault To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Commvault between April 29, 2025 and January 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Commvault Systems, Inc. ("Commvault" or the "Company") (NASDAQ: CVLT) and reminds investors of the July 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Microsoft remains a Strong Buy as the market misreads recent headlines and undervalues its AI-driven strategy. Meta Compute's entry pressures neoclouds, not MSFT, and validates AI infrastructure pricing above build cost, supporting MSFT's CapEx returns. The MAI model insourcing directly addresses gross margin compression, with Copilot and product consolidation enhancing cost efficiency and future profitability.

Does Zions (ZION) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does CSX (CSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Consensus Cloud Solutions, Inc. (CCSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Datadog (DDOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Cimpress (CMPR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).